Business Wire

Verimatrix Launches Streamkeeper To Offer Industry’s First Battle-Ready Cybersecurity Solution Engineered to Hunt Down and Take Out Video Piracy

29.11.2021 19:45:00 EET | Business Wire | Press release

Share

Regulatory News:

Verimatrix, (Euronext Paris: VMX) (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced the launch of its new Verimatrix StreamkeeperSM solution, a cybersecurity and anti-piracy gamechanger for the media & entertainment industry. Streamkeeper empowers customers to hunt down and take out OTT pirates who steal content such as live sports and premium movie as they are distributed from the source to the endpoint (mobile app/user level).

The solution includes Verimatrix's all-new CounterspySM technology -- the autonomous injection of an anti-piracy and app protection security agent that utilizes the company’s proprietary zero code technology which allows customers to add deep, defensive countermeasures, plus monitor their clients without the hassle of a huge integration effort. Integration efforts have also been reduced dramatically, from months to minutes, accompanying numerous operator benefits ranging from a reduction in siphoned subscribers to expanded access to valuable, highly sought-after studio content.

Streamkeeper enables OTT operators to delight studios and other content owners with powerful piracy visibility and protections. Operators also have full control of the visibility offered to content owners. Creative hackers often weaponize CDNs and end device software such as mobile apps and web browsers – using them against operators. Verimatrix’s groundbreaking Counterspy zero-code injection approach shines a light on previously hidden piracy attacks, leaving pirates with no place to hide. The battle-ready tools provided within Streamkeeper allow customer to fight piracy with powerful, military-grade cybersecurity countermeasures never before available. Currently in beta testing and examined by studios, Verimatrix Streamkeeper is scheduled for general availability at the end of Q1 2022.

“Streamkeeper is a game-changing new OTT anti-piracy solution that will forever change how Hollywood and sports will tackle piracy,” said Asaf Ashkenazi, Chief Operating Officer and President at Verimatrix. “It’s a complete content security package containing exciting new technologies, such as the autonomous injection of an anti-piracy security agent that utilizes zero code technology; meaning we can now easily add deep, defensive anti-piracy tracing, app protection and countermeasures instantly to customer ecosystems. Content owners and operators have been seeking a solution such as Streamkeeper that leaves no low-hanging fruit for pirates to exploit and does so in a way that empowers the industry while maintaining great user experiences and protecting investments in content. We believe this solution could become the de facto standard for next-generation anti-piracy, recommended by content owners.”

Significantly different from any other solution available on the market today, Streamkeeper closes authentication gaps and harnesses app protection and dual-telemetry technology to monitor new/unknown hacking attempts and real-time tampering and content theft. This arms operators with the ability to identify suspected piracy and react instantly with a variety of countermeasures. Working in tandem with time-tested Multi-DRM, fingerprinting/watermarking and dark web crawling to track down pirated content in bold new ways, Streamkeeper takes anti-piracy far beyond reveal and takedown notices -- enabling alert verification as well as views into the actual apps, devices and users accessing authorized and unauthorized content during livestreams. This empowers customers to more aggressively combat pirates at the endpoint should they choose, or deploy less aggressive responses such as degradation of screen quality or in-broadcast messaging. The ability to halt live streaming pirated content in real-time is an incredibly powerful tool.

Top highlights inside Verimatrix Streamkeeper include:

  • Multi-DRM enhanced with one-time authentication tokens
  • Compatible with all studio-approved DRM solutions
  • App Shield and telemetry-based investigations at the app/user level
  • Covers clients build on mobile apps as well as web apps
  • Edge Authenticator protects access to CDN and secures service platform
  • Watermarking with hardened client application
  • Counterspy zero-code injection of an anti-piracy security agent
  • Reveal pirates and enable counter measures like throttle, slowdown or shutdown
  • Data collection filtered/refined by AI and machine learning
  • Dashboard that predicts risks, tracks trends & infringers

For more information on Verimatrix Streamkeeper, including a demo or becoming a beta customer, visit: www.verimatrix.com/streamkeeper/

About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Verimatrix Investor Contact:
Jean-François Labadie, Chief Financial Officer
finance@verimatrix.com

Verimatrix Media Contact:
Matthew Zintel
matthew.zintel@zintelpr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye